Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
July 01 2022 - 7:40AM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage
pharmaceutical company with a Research & Development
(“R&D”) innovation engine that aims to discover, develop and
ultimately deliver impactful medicines to patients, today announced
the appointment of Mathias Hukkelhoven, Ph.D., formerly
Senior Vice President, Global Regulatory, Safety & Biometrics
at Bristol Myers Squibb (BMS), to its Board of Directors. In
addition, the Company announced that Aaron Kantoff has resigned
from the Company’s Board, but will remain actively involved with
the Company as an advisor. Both changes are effective July 1,
2022.
“I am very pleased to welcome Math to Centessa’s Board of
Directors. Math’s deep industry experience in leading global
regulatory and development efforts for novel therapeutics will be
extremely valuable as we continue to advance our rare disease and
immuno-oncology pipeline of potential best-in-class medicines for
patients,” said Saurabh Saha, MD, PhD, Chief Executive Officer of
Centessa. “I would also like to thank Aaron for his significant
contributions to the Centessa Board which have helped progress our
business from inception through our successful IPO to where we are
today.”
“I’m excited to join the Centessa Board at such a pivotal time
for the Company,” said Dr. Hukkelhoven. “I have been impressed by
Centessa’s leadership team, vision, and exciting portfolio, and I
look forward to working with the Board and the team to advance
these potential therapies through proof of concept readouts with
the ultimate goal of fulfilling unmet needs for patients.”
Dr. Hukkelhoven is an experienced global regulatory and drug
development leader. He previously served as Senior Vice President,
Global Regulatory, Safety & Biometrics at BMS and was also
responsible for the R&D Group in BMS China and the Clinical
Pharmacology and Pharmacometrics group. In these roles, Dr.
Hukkelhoven was accountable for setting regulatory strategy and
driving execution of global regulatory and pharmacovigilance plans
for BMS. Prior to joining BMS, Dr. Hukkelhoven held the role of
Chairman Portfolio Stewardship Board at Novartis Pharmaceutics and
served as the Senior Vice President, Global Head Drug Regulatory
Affairs at Novartis from 2001 to 2009. He also worked at Hoffmann
LaRoche (Switzerland) and Organon (The Netherlands). Dr.
Hukkelhoven has served as chairperson of the Regulatory Affairs
Coordinating Committee at PhRMA, and recently as a PhRMA negotiator
for the PDUFA VII negotiations with the U.S. Food and Drug
Administration (FDA). Dr. Hukkelhoven received his BS and PhD with
honors in Biology and Biochemistry from the University of Nijmegen,
the Netherlands. Dr. Hukkelhoven also serves on the Board of
Directors of Compugen Ltd, and is a Senior Advisor to McKinsey and
an R&D Strategy Advisor to LianBio.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical
company with an R&D innovation engine that aims to discover,
develop and ultimately deliver impactful medicines to patients. Our
programs span discovery-stage to late-stage development and cover a
range of high-value indications in rare diseases and
immuno-oncology. We are led by a management team with extensive
R&D experience, providing direct guidance to our program teams
to rapidly advance our candidates from research through all stages
of development. For more information, visit www.centessa.com, which
does not form part of this release.
Forward Looking Statements
This press release contains forward-looking statements. These
statements may be identified by words such as “may,” “might,”
“will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“objective,” “anticipate,” “believe,” “estimate,” “predict,”
“potential,” “continue,” “ongoing,” “aim,” “seek,” and variations
of these words or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including statements regarding the
expected benefits of Dr. Hukkelhoven’s service on the Board of
Directors of Centessa; statements related to the Company’s ability
to deliver impactful medicines to patients; the ability of our key
executives to drive execution of the Company’s portfolio of
programs; our asset-centric business model and the intended
advantages and benefits thereof; and research and clinical
development plans and the timing thereof. Any forward-looking
statements in this press release are based on our current
expectations, estimates and projections only as of the date of this
release and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks related to the safety and tolerability profile of our product
candidates; our ability to protect and maintain our intellectual
property position; business (including commercial viability),
regulatory, economic and competitive risks, uncertainties,
contingencies and assumptions about the Company; risks inherent in
developing products and technologies; future results from our
ongoing and planned clinical trials; our ability to obtain adequate
financing, including through our financing facility with Oberland,
to fund our planned clinical trials and other expenses; trends in
the industry; the legal and regulatory framework for the industry,
including the receipt and maintenance of clearances to conduct or
continue clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of preclinical studies or
clinical studies will not be predictive of future results in
connection with future studies; geo-political risks such as the
Russia-Ukraine war and risks related to the ongoing COVID-19
pandemic including the effects of the Delta, Omicron and any other
variants. These and other risks concerning our programs and
operations are described in additional detail in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2022, and our
other reports, which are on file with the U.S. Securities and
Exchange Commission. We explicitly disclaim any obligation to
update any forward-looking statements except to the extent required
by law.
Contact:
Kristen K. Sheppard, Esq.SVP of Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Oct 2023 to Oct 2024